Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ertugliflozin

FDA-approved product (tablet, oral), marketed as Ertugliflozin, Steglatro.

Registered studies
49
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ertugliflozin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Ertugliflozin. Its therapeutic class is shown instead.

WHO therapeutic group
Sodium-glucose co-transporter 2 (sglt2) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ertugliflozin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ertugliflozin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial Infarction

    NCT07621380 · start 2026-07-01

    Registered record
    Registry ID
    NCT07621380
    Conditions
    Type 2 Diabetes Mellitus Myocardial Infarction
    Interventions
    Ertugliflozin 10 mg; Standard AMI Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2028-03-01
    Enrolment
    476

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus Myocardial Infarction
    InterventionErtugliflozin 10 mg; Standard AMI Care
    PhasePhase 4
    Registry statusNot yet recruiting

  • Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

    NCT07547878 · start 2026-04-30

    Registered record
    Registry ID
    NCT07547878
    Conditions
    Chronic Kidney Disease; Type 2 Diabetes
    Interventions
    Finerenone; Semaglutide; Lotensin; Capoten; Enalapril; Monopril; Lisinopril; Univasc; Aceon; Accupril; Altace; Mavik; Edarbi; Atacand; Avapro; Cozaar; Benicar; Micardis; Diovan; Invokana; Farxiga; Jardiance; Ertugliflozin; Brenzavvy; Sotagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-04-30
    Completion
    2029-03-31
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Type 2 Diabetes
    InterventionFinerenone; Semaglutide; Lotensin; Capoten +21 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

    NCT07188545 · start 2025-09-15

    Registered record
    Registry ID
    NCT07188545
    Conditions
    Cardiovascular Kidney Metabolic Syndrome
    Interventions
    Intervention; Active Comparator
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2025-09-15
    Completion
    2029-06-30
    Enrolment
    23,280,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Kidney Metabolic Syndrome
    InterventionIntervention; Active Comparator
    PhaseNot recorded
    Registry statusActive not recruiting

  • Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets in Healthy, Adult, Human Subjects Under Fed Condition.

    NCT07266779 · start 2025-08-22

    Registered record
    Registry ID
    NCT07266779
    Conditions
    Type 2 Diabetes
    Interventions
    Ertugliflozin/Metformin film coated tablets; Segluromet film coated tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-08-22
    Completion
    2025-10-11
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionErtugliflozin/Metformin film coated tablets; Segluromet film coated tablets
    PhasePhase 1
    Registry statusCompleted

  • ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy

    NCT06580717 · start 2024-10-15

    Registered record
    Registry ID
    NCT06580717
    Conditions
    Nonobstructive Hypertrophic Cardiomyopathy
    Interventions
    enavogliflozin 0.3mg; enavogliflozin Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-10-15
    Completion
    2026-11-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNonobstructive Hypertrophic Cardiomyopathy
    Interventionenavogliflozin 0.3mg; enavogliflozin Placebo
    PhasePhase 4
    Registry statusRecruiting

  • Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

    NCT06449235 · start 2024-09

    Registered record
    Registry ID
    NCT06449235
    Conditions
    Type2diabetes
    Interventions
    Omarigliptin; Sulphonylureas; Metformin; Other DPP4-i; Thiazolidinediones; Alpha-Glucosidase Inhibitor; Glucagon-Like Peptide-1; Receptor Agonists (GLP1RA); SGLT2 inhibitors
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-09
    Completion
    2025-06
    Enrolment
    938

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType2diabetes
    InterventionOmarigliptin; Sulphonylureas; Metformin; Other DPP4-i +5 more
    PhasePhase 4
    Registry statusUnknown

  • DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes

    NCT06983054 · start 2023-07-25

    Registered record
    Registry ID
    NCT06983054
    Conditions
    Type 2 Diabetes
    Interventions
    ertugliflozine; low salt diet; placebo; high salt diet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-07-25
    Completion
    2025-12
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    Interventionertugliflozine; low salt diet; placebo; high salt diet
    PhasePhase 4
    Registry statusRecruiting

  • DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study

    NCT05727579 · start 2023-07-03

    Registered record
    Registry ID
    NCT05727579
    Conditions
    Diabetes Mellitus; Diabetic Kidney Disease; Hypertension
    Interventions
    Salt-Diet and/or Ertugliflozin; Ertugliflozin 15 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-07-03
    Completion
    2025-11-30
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus; Diabetic Kidney Disease; Hypertension
    InterventionSalt-Diet and/or Ertugliflozin; Ertugliflozin 15 mg
    PhasePhase 4
    Registry statusCompleted

  • Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers

    NCT05662865 · start 2023-03-16

    Registered record
    Registry ID
    NCT05662865
    Conditions
    Ketones, Metabolism
    Interventions
    SGLT2 inhibitor; Controlled, Adaptive Study Diet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2023-03-16
    Completion
    2026-12
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKetones, Metabolism
    InterventionSGLT2 inhibitor; Controlled, Adaptive Study Diet
    PhasePhase 1
    Registry statusActive not recruiting

  • Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD

    NCT05644717 · start 2023-03-01

    Registered record
    Registry ID
    NCT05644717
    Conditions
    Liver Fat; Liver Fibrosis; Glycemic Control; Body Weight Changes; Waist Circumference; Tolerance
    Interventions
    Ertugliflozin 5 mg, 15mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-03-01
    Completion
    2025-12-01
    Enrolment
    164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Fat; Liver Fibrosis; Glycemic Control; Body Weight Changes +2 more
    InterventionErtugliflozin 5 mg, 15mg
    PhasePhase 4
    Registry statusRecruiting

  • ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF

    NCT05152940 · start 2023-02-02

    Registered record
    Registry ID
    NCT05152940
    Conditions
    Heart Failure With Reduced Ejection Fraction; Congestion
    Interventions
    Ertugliflozin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-02-02
    Completion
    2023-10-27
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Reduced Ejection Fraction; Congestion
    InterventionErtugliflozin; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study

    NCT05556291 · start 2022-12-01

    Registered record
    Registry ID
    NCT05556291
    Conditions
    Efficacy; Safety; Tolerability
    Interventions
    Combinations of Oral Blood Glucose Lowering Drugs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-12-01
    Completion
    2024-12-01
    Enrolment
    190

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEfficacy; Safety; Tolerability
    InterventionCombinations of Oral Blood Glucose Lowering Drugs
    PhaseNot recorded
    Registry statusCompleted

  • Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients

    NCT05477017 · start 2022-09

    Registered record
    Registry ID
    NCT05477017
    Conditions
    Type2Diabetes
    Interventions
    SGLT2 inhibitor
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-09
    Completion
    2023-03
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType2Diabetes
    InterventionSGLT2 inhibitor
    PhaseNot recorded
    Registry statusUnknown

  • Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

    NCT05220917 · start 2021-08-01

    Registered record
    Registry ID
    NCT05220917
    Conditions
    Cardiovascular Events; Type2 Diabetes; Renal Disease
    Interventions
    SGLT2 inhibitor; DPP-4 inhibitor; GLP-1RA; 2nd generation SU
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2021-08-01
    Completion
    2027-09-30
    Enrolment
    781,430

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Events; Type2 Diabetes; Renal Disease
    InterventionSGLT2 inhibitor; DPP-4 inhibitor; GLP-1RA; 2nd generation SU
    PhaseNot recorded
    Registry statusActive not recruiting

  • BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

    NCT05161429 · start 2021-07-01

    Registered record
    Registry ID
    NCT05161429
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    DPP4; GLP-1 receptor agonist; Basal Insulin; SLGT2; SU
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-07-01
    Completion
    2024-06-30
    Enrolment
    550,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionDPP4; GLP-1 receptor agonist; Basal Insulin; SLGT2 +1 more
    PhaseNot recorded
    Registry statusUnknown